GraniteShares Advisors LLC Has $381,000 Stake in United Therapeutics Corporation $UTHR

GraniteShares Advisors LLC lifted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 4.1% during the second quarter, Holdings Channel.com reports. The firm owned 1,327 shares of the biotechnology company’s stock after buying an additional 52 shares during the quarter. GraniteShares Advisors LLC’s holdings in United Therapeutics were worth $381,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Vaughan Nelson Investment Management L.P. bought a new position in United Therapeutics during the 1st quarter worth $101,354,000. Nuveen LLC bought a new position in United Therapeutics during the first quarter worth about $83,533,000. Amundi raised its stake in United Therapeutics by 198.8% in the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after purchasing an additional 232,988 shares in the last quarter. GAMMA Investing LLC boosted its holdings in United Therapeutics by 29,415.2% in the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock valued at $68,422,000 after purchasing an additional 221,202 shares during the period. Finally, Acadian Asset Management LLC grew its position in shares of United Therapeutics by 1,657.8% during the 1st quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company’s stock worth $55,217,000 after purchasing an additional 169,010 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on UTHR. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Wells Fargo & Company increased their target price on United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a report on Wednesday, September 3rd. UBS Group raised their price target on United Therapeutics from $415.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, September 4th. Finally, HC Wainwright upped their price objective on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. Ten equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $448.14.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Insiders have sold 192,935 shares of company stock valued at $73,905,462 over the last quarter. Company insiders own 10.30% of the company’s stock.

United Therapeutics Trading Up 1.7%

Shares of NASDAQ UTHR opened at $432.66 on Monday. The company has a market cap of $19.52 billion, a price-to-earnings ratio of 16.89, a PEG ratio of 6.60 and a beta of 0.62. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $442.01. The stock has a 50-day moving average price of $342.90 and a two-hundred day moving average price of $314.85.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same period last year, the firm posted $5.85 earnings per share. On average, sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.